Answers are grounded in this paper and cite their sources.
Background: Peripheral neuropathy is a common complication of diabetes mellitus, contributing the greatest morbidity and mortality and impairing the quality of life. Recently the receptor of erythropoietin (Epo) was proven to be expressed in neuronal cell and recombinant human Epo (rhEpo) has been shown to have neuroprotective and neurotrophic potential in peripheral neuropathy. But there is no report about baseline Epo level in blood before rhEpo treatment with diabetic peripheral neuropathy.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: